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Correction of Tetralogy of Fallot
Juho Keski-Nisula, MD, Eero Pesonen, MD, PhD, Klaus T. Olkkola, MD, PhD,
Terri Ahlroth, RN, Juha Puntila, MD, Sture Andersson, MD, PhD,
Pertti J. Neuvonen, MD, PhD, and Pertti K. Suominen, MD, PhD
Department of Anesthesia and Intensive Care, Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki;
Department of Anesthesiology, Intensive Care, and Pain Medicine, Meilahti Hospital, University of Helsinki and Helsinki University
Hospital, Helsinki; Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Helsinki and
Helsinki University Hospital, Helsinki; Department of Pediatric Surgery, Children’s Hospital, University of Helsinki and Helsinki
University Hospital, Helsinki; Department of Neonatal Intensive Care, Children’s Hospital, University of Helsinki and Helsinki
University Hospital, Helsinki; and Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University
Hospital, Helsinki, FinlandBackground. The optimal dose of methylprednisolone
during pediatric open heart surgical procedures is un-
known. This study compared the antiinflammatory and
cardioprotective effects of high and lower doses of
methylprednisolone in children undergoing cardiac
operations.
Methods. Thirty children, between 1 and 18 months
old and undergoing total correction of tetralogy of Fallot,
were randomized in double-blind fashion to receive
either 5 or 30 mg/kg of intravenous methylprednisolone
after anesthesia induction. Plasma concentrations of
methylprednisolone, interleukin-6 (IL-6), IL-8, and IL-10,
troponin T, and glucose were measured at anesthesia
induction before administration of the study drug, at 30
minutes on cardiopulmonary bypass (CPB), just after
weaning from CPB, and at 6 hours after CPB. Troponin T
and blood glucose were also measured on the first post-
operative morning.Accepted for publication Feb 25, 2016.
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Published by ElsevierResults. Significantly higher methylprednisolone con-
centrations were measured in patients receiving 30 mg/kg
of methylprednisolone at 30 minutes on CBP, after
weaning from CPB and at 6 hours after CPB (p < 0.001).
No differences were detected in IL-6, IL-8, IL-10, or
troponin concentrations at any time point. Blood glucose
levels were significantly higher in patients receiving 30
mg/kg of methylprednisolone at 6 hours after CPB (p [
0.04) and on the first postoperative morning (p [ 0.02).
Conclusions. Based on the measured concentrations of
interleukins or troponin T, a 30 mg/kg dose of methylpred-
nisolone during pediatric open heart operations does not
offer any additional antiinflammatory or cardioprotective
benefit over a 5 mg/kg dose. Higher dose of methylprednis-
olone exposes patients more frequently to hyperglycemia.
(Ann Thorac Surg 2016;102:870–6)
 2016 by The Society of Thoracic Surgeonshe antiinflammatory effect of corticosteroids duringTpediatric open heart surgical procedures was sub-
stantiated in several studies [1–4]. Although some ran-
domized studies reported that corticosteroids reduced
perioperative troponin release, the clinically meaningful
cardioprotective effect is questionable [5–8]. In addition,
the effect on clinical outcome after pediatric heart oper-
ations is controversial. The use of steroids has been
associated with improved hemodynamics and shortened
duration of postoperative mechanical ventilation and
intensive care stay [9, 10]. Conversely, steroids have been
noted to increase morbidity, especially in lower-risk pe-
diatric cardiac patients, and previous studies showed apossible association of steroids with increased number of
infections, hyperglycemia, and possible perioperative
renal dysfunction [4, 8, 11–13].
The protocols of steroid administration vary among
different pediatric cardiac centers [14, 15]. According to
an international survey the two most common practices of
administration are a single dose of steroid either at the
induction of anesthesia or perioperatively in the cardio-
pulmonary bypass (CPB) prime [14]. We noted in a recent
study that methylprednisolone (MP) administration at
anesthesia induction was more effective for antiin-
flammatory purposes than administration in the CPB
circuit [9]. Both administration routes decreased troponin
T levels at the same extent but exposed patients to hy-
perglycemia compared with placebo.
In the present study we compared a single dose of 30
mg/kg of preoperative intravenous MP with a dose of 5
mg/kg of MP in children between 1 and 18 months old
who were undergoing primary surgical total correction of0003-4975/$36.00
http://dx.doi.org/10.1016/j.athoracsur.2016.02.089
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tetralogy of Fallot. Our hypothesis was that administra-
tion of 30 mg/kg of MP at anesthesia induction would
lead to significantly higher plasma concentrations of MP
and produce better antiinflammatory and car-










Ethics and Informed Consent
The study protocol was approved by the Ethics Com-
mittee of Helsinki University Hospital and also by the
Finnish Medicines Agency. It was registered in the Eu-
ropean Union Drug Regulating Authorities Clinical Trials
(Eudra-CT 2008-007413-76). Written informed consent
was obtained from the parents of each participating study
patient before the study commenced.
Study Design
This randomized (sealed envelope), double-blind study
included 30 patients, between 1 and 18 months of age who
were having total correction of tetralogy of Fallot. Exclusion
criteria were as follows: prematurity, defined as gestational
age of less than 36 weeks; previous cardiac surgical
procedures; and preoperative steroid treatment. After
anesthesia induction, placement of the arterial line, and
collection of the first study plasma sample, patients were
randomized to receive either 5 or 30 mg/kg of intravenous
MP. A pharmacist whowas not involved in the care of these
patients prepared the MP solutions. The syringes of the
study drug were covered with nontransparent paper foil.
According the study protocol, no additional perioperative
steroids were given to study patients.
Intraoperative Management
Balanced anesthesia was attained with sufentanil, pan-
curonium, propofol or (S)-ketamine, and sevoflurane.
Myocardial protection and CBP were accomplished by
using the methods described previously [16]. Patients
received 30 mL/kg of cold blood cardioplegia after aortic
cross-clamp, and 10 mL/kg of cardioplegia was then
administered every 20 minutes. Terminal tepid car-
dioplegia was administered before declamping of the
aorta. Because of prolonged study patient recruitment
time, the cardioplegia administration protocol changed in
our department during the study period. The 6 last pa-
tients (3 in each study group) received a 2-minute infu-
sion of cold (24C) blood cardioplegia, mixed at a ratio of
1:1 (blood to cardioplegia) during aortic cross-clamp, and
thereafter, a 1-minute infusion of cold blood cardioplegia
was administered every 20 minutes. Terminal tepid car-
dioplegia was not administered to these patients.
Approximately 4 mg/kg of sodium heparin was used for
anticoagulation before CPB, and the Hepcon HMS Plus
Hemostasis Management System (Medtronic, Minneap-
olis, MN) was used to obtain the target heparin concen-
tration of 6 units/mL during CPB. Protamine sulfate was
used to reverse the anticoagulant effect of heparin after
patients were weaned from CPB. All the study patients
received a bolus of 30,000 KIU/kg (4.2 mg/kg) of aprotininbefore CPB and a continuous infusion of 30,000 KIU/kg/h
(4.2 mg/kg/h) during CPB.
Inotropes and Insulin
Milrinone was used for all patients as the first-line
inotropic drug. Epinephrine and norepinephrine were
added to milrinone for hemodynamic support when
needed. Five patients (1 patient in the 5 mg/kg MP group
and 4 patients in the 30 mg/kg MP group) received
perioperative phenylephrine because of cyanotic spells.
Levosimendan was used for 1 patient in the 5 mg/kg MP
group and for 2 patients in the 30 mg/kg MP group. In-
sulin was administered in the pediatric intensive care unit
(PICU) as deemed necessary by the clinician in charge. In
general, insulin infusion was started when blood glucose
concentrations were greater than 12 mmol/L in two
consecutive measurements.
Blood Samples
In this study, 5 mL of arterial blood was collected into
tubes containing sodium citrate at four different time
points: T1, after anesthesia induction before administra-
tion of MP; T2, 30 minutes after initiation of CPB; T3, 5
minutes after administration of protamine; and T4, 6
hours after cessation of CPB. Plasma was separated
immediately by centrifugation and was stored at 70C
until analysis. Interleukin-6 (IL-6), IL-8, and IL-10 were
determined at time points T1 to T4 by using commercial
enzyme-linked immunosorbent assay kits (Quantikine,
R&D Systems, Abington, United Kingdom). Total plasma
concentration of MP was determined at time points T2 to
T4 by using a high-performance liquid chromatography–
electrospray–tandem mass spectrometry method [17].
The lower limit of MP quantification was 2 ng/mL, and
the interday coefficient of variation was less than 10%.
Troponin T concentrations were determined using an
electrochemiluminescence immunoassay (Elecsys 2010
immunoanalyzer, Roche Diagnostics, Berlin, Germany) at
time points T1, T3, and T4 and at 6 o’clock on the first
postoperative morning. Blood glucose was collected for
study purposes at time points T1, T2, T3, and T4 and at 6
o’clock on the first postoperative morning.
Statistical Analysis
Plasma concentrations of MP, IL-6, IL-8, IL-10, and
troponin T were used as primary outcome measures.
Blood glucose level served as a secondary outcome
measure. Pertinent physiologic and clinical parameters
were also collected and analyzed even though they were
not study endpoints. Calculations of previous study data
indicated that 12 patients would be required to demon-
strate a 20% difference in IL-6 values between the two
study groups (a ¼ 0.05, 1-b ¼ 0.8) [3]. Fifteen patients were
enrolled in both study groups to compensate for possible
dropouts. One dropout in the MP 5 mg/kg group
occurred because of cancellation of the operation after
randomization.
Data were analysed using GraphPad Prism 5.0a for
Macintosh (GraphPad Software, La Jolla, CA). Plasma
concentrations of cytokines and troponin were not
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normally distributed; thus, we used the Mann-Whitney U
test for the comparisons between the groups. The c2 test
was used for comparison of frequencies between the two
groups; p values less than 0.05 were considered to be
statistically significant. Data are expressed as medians
and interquartile range.Results
Demographic data with no significant differences are
presented in Table 1. Significantly higher mean MP
concentrations (p < 0.001) were measured at every time
point T2, T3, and T4 in patients who received intravenous
MP 30 mg/kg compared with the dose of 5 mg/kg (Fig 1).
However, no significant differences were observed be-
tween the study groups in concentrations of inflammatory
interleukins IL-6 (p ¼ 0.59 to 0.95) and IL-8 (p ¼ 0.45 to
0.91) or in the levels of antiinflammatory IL-10 (p ¼ 0.37 to
0.68) at any of the time points (Fig 2). Moreover, the
troponin T levels of both study groups were similar at all
the measured time points (p ¼ 0.38 to 0.98) (Fig 3).
Administration of 30 mg/kg of MP resulted in higher
blood glucose concentrations at 6 hours after CPB (p ¼
0.04) and on the first postoperative morning (p ¼ 0.02)
(Fig 1). Four patients in the MP 30 mg/kg group received
insulin versus none in the MP 5 mg/kg group (p ¼ 0.04).
Seven patients in the MP 30 mg/kg group received
amiodarone infusion because of postoperative junctional
ectopic tachycardia or atrial tachycardia versus 2 patients
in the MP 5 mg/kg group (p ¼ 0.06).
The postoperative laboratory and clinical data are
presented in Table 2. No significant differences were
found for postoperative lactate levels, central venous
saturation, inotropic score, or levels of N-terminal pro–B-




Age (months) 5.8 (3.6






Preoperative b-blocker for cyanotic spells (n)
CPB support time (min) 99 (79,
Aortic cross-clamp time (min) 62 (52,




Primary sternal closure (n)
Late repeat sternotomy (n)
a Values are medians and interquartile range.
CPB ¼ cardiopulmonary bypass; MP ¼ methylprednisolone.blood leukocyte count was similar for both groups. Two
cases of postoperative infection, one case of pneumonia,
and one case of mediastinitis occurred in the MP 30 mg/
kg group. The duration of mechanical ventilation or PICU
stay did not differ between the groups. One patient in the
MP 5 mg/kg group needed postoperative extracorporeal
life support during 6 days because of severe tricuspid
valve leakage, unstable hemodynamics, and poor respi-
ratory function. The patient was weaned form extracor-
poreal life support and recovered successfully. No deaths
occurred during the 30-day follow-up period.Comment
Administration of intravenous 30 mg/kg MP after anes-
thesia induction produced remarkably higher drug con-
centrations than did 5 mg/kg of MP. Even so, no benefit
for antiinflammatory, cardioprotective, or clinical
outcome was found. Patients who received high-dose MP
had more hyperglycemia and concomitant need for in-
sulin therapy. Our results discourage the use of high-dose
30 mg/kg MP and endorse the use of lower MP doses with
equal antiinflammatory and possible cardioprotective
effects and a lower incidence of hyperglycemia.
Despite producing adverse effects, high-dose steroid
administration is common during pediatric cardiac surgi-
cal procedures [14, 15]. The complex nongenomic and
genomic mechanisms of glucocorticoids in antiin-
flammatory action are still under discussion. Classically
the therapeutic antiinflammatory effect of steroids has
been described to be mediated through genomic trans-
repression of genes encoding inflammatory mediators. In
transrepression, steroid-activated glucocorticoid receptor
interferes with the activity of proinflammatory transcrip-
tion factors, such as activator protein 1 (AP-1) and nuclearmg/kg
¼ 14)
MP 30 mg/kg
(n ¼ 15) p Value
, 8.6) 5.3 (4.2, 9.0) 0.71







107) 95 (79, 122) 0.75
80) 60 (51, 89) 0.68





Fig 1. Plasma concentrations (median, interquartile range) of meth-
ylprednisolone (MP) and blood glucose in the MP 30 mg/kg and MP 5
mg/kg groups at different time points: T1, after anesthesia induction
before administration of MP; T2, 30 minutes after initiation of car-
diopulmonary bypass; T3, 5 minutes after protamine administration;
T4, 6 hours after cessation of cardiopulmonary bypass; and 1. POD,
on the first postoperative morning. Statistically significant differences
are marked with one asterisk for p < 0.05 and with two asterisks for
p < 0.0001.
Fig 2. Plasma concentrations (median, interquartile range) of
interleukin-6 (IL-6), IL-8, and IL-10 in the methylprednisolone (MP)
30 mg/kg and MP 5 mg/kg groups at different time points: T1, after
anesthesia induction before administration of MP; T2, 30 minutes
after initiation of cardiopulmonary bypass; T3, 5 minutes after
protamine administration; and T4, 6 hours after cessation of
cardiopulmonary bypass. No statistically significant (p < 0.05)
differences were noted in concentrations between the groups.
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factor kB (NF-kB), and leads to down-regulation of proin-
flammatory protein synthesis [18]. More recently, in-
vestigators have also noted that transactivation plays
an essential role in the antiinflammatory action of steroids
[18, 19]. In transactivation, the dimerized glucocorticoid
receptor-protein complex binds to the promoter of
glucocorticoid-regulated genes, thus inducing the expres-
sion of specific antiinflammatory genes and proteins such
as NF-kB inhibitor, dual-specificity phosphatase (DUSP) 1,
IL-10, glucocorticoid-induced leucine zipper (GILZ), and
AnnexinA1 [18]. Transactivation is also largely responsible
for glucocorticoid metabolic and adverse effects as a result
of enhanced expression of genes involved in metabolic
processes [20]. In addition, investigators have noted
that inhibition of AP-1 and NF-kB activities and the
antiinflammatory effect is produced by much lowerglucocorticoid concentration than is transactivation [21].
This action may at least partly explain the increased
adverse effects with higher corticosteroid doses. Notably,
Fig 3. Plasma concentrations (median, interquartile range) of
troponin T in the methylprednisolone (MP) 30 mg/kg and MP 5 mg/
kg groups at different time points: T1, after anesthesia induction
before administration of MP; T3, 5 minutes after protamine admin-
istration; T4, 6 hours after cessation of cardiopulmonary bypass; and
1. POD, on the first postoperative morning. No statistically signifi-
cant (p < 0.05) differences were noted in concentrations of troponin
T between the groups.
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the MP concentrations after high-dose administration in
our study remainedhigher at 6hours afterCPB thandid the
measured peak concentration in the lower-dose group that
may prolong the existence of unwanted side effects such as
hyperglycemia (Fig 1).
A previous study in pediatric cardiac patients
compared the antiinflammatory effect of a single high




Arrival to intensive care unit
Lactate (mmol/L) 1.25 (0.1, 1.7)
White blood cell count (E9/L) 10.5 (9.8, 13.8)
Rectal temperature (C) 35.9 (35.5, 36.4)
Inotropic score 16.0 (11.5, 23.6)
Central venous saturation (%) 60.4 (39.0, 69.6)
First postoperative daya
Lactate (mmol/L) 1.1 (0.9, 1.5)
White blood cell count (E9/L) 13.5 (11.7, 15.7)
Rectal temperature (C) 37.5 (37.4, 37.9)
Inotropic score 5.1 (5.0, 7.6)
Central venous saturation (%) 63.4 (61.6, 6.9)
NT-proBNP 7,161 (4,990, 11,24
Ventilatory treatment (days) 1.1 (0.5, 1.5)
Intensive care unit stay (days) 2.5 (2.0, 4.0)
a Measured on the first postoperative day at 6:00 hours, except the inotropic s
range.
MP ¼ methylprednisolone; NT-proBNP ¼ N-terminal pro–B-type natriureof 2 mg/kg MP [2]. In accordance with our study, no
beneficial antiinflammatory effect was demonstrated with
high-dose steroid use in the study of Varan and col-
leagues [2]. Although the present study was not placebo
controlled, the antiinflammatory effect of glucocorticoids
during pediatric open heart operations has been
demonstrated in previous studies [1, 4, 7, 8]. The preop-
erative administration during anesthesia induction has
been noted to be more effective for antiinflammatory
purposes than the intraoperative administration in CPB
prime solution [8]. In a study by Graham and associates
[13] in neonates undergoing cardiac surgical procedures,
the combined preoperative and perioperative adminis-
tration of 30 mg/kg of MP decreased the levels of IL-6
compared with a single preoperative administration.
Nonetheless, the combined administration of MP did not
improve the clinical outcome. In that study the two-dose
MP regimen was associated with higher serum creatinine
values and poorer postoperative diuresis [13].
Corticosteroids induce hyperglycemia by several
mechanisms, and hyperglycemia becomes more frequent
with increasing doses and longer duration of treatment.
Corticosteroids increase the endogenous glucose pro-
duction by activating genes involved in hepatic gluco-
neogenesis [22]. These drugs also enhance the effects of
glucagon and epinephrine, thereby further increasing the
synthesis of endogenous glucose. Corticosteroids also
reduce peripheral glucose uptake by causing insulin
resistance of the muscular and other peripheral tissues.
Depending on dose and duration of treatment, cortico-
steroids also inhibit insulin production and secretion
from pancreatic b cells [22]. In randomized clinical trials,
tight glycemic control (blood glucose 4.4 to 6.1 mmol/L)
did not reduce the rate of infections, mortality rate, length
of stay, measures of organ failure, or need for mechanicalMP 30 mg/kg
(n ¼ 15) p Value
1.5 (1.2, 1.8) 0.31
11.2 (10.2, 12.1) 0.93
36.0 (35.2, 36.3) 0.76
23.3 (16.7, 26.3) 0.12
61.3 (53.5, 73.4) 0.44
1.2 (0.9, 1.6) 0.78
13.4 (10.8, 15.7) 0.97
37.4 (37.1, 37.7) 0.09
6.9 (5.1, 13.0) 0.11
61.5 (52.9, 71.5) 0.48
8) 7,221 (4,491, 8,765) 0.71
1.2 (0.8, 3.3) 0.36
4.0 (2.0, 7.0) 0.19
core was calculated at 12:00 hours. Values are medians and interquartile
tic peptide.
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ventilation compared with standard care after pediatric
cardiac operations [23, 24]. Nonetheless, hyperglycemia
has been associated with several detrimental effects in
critically ill children. Vlasselaers and associates [25] noted
that targeting of blood glucose to age-adjusted normal
fasting concentrations improves short-term outcome of
patients in the PICU. Faustino and Apkon [26] detected
that hyperglycemia is frequent in patients in the PICU
and is associated with greater hospital mortality rates and
increased length of stay. Yates and colleagues [27] re-
ported in a retrospective study that hyperglycemia is
associated with increased organ dysfunction, infection,
duration of ventilator treatment, PICU and hospital stay,
and mortality rates in small children after cardiac oper-
ations. Moreover, in a retrospective cohort by Tala and
associates [28], hyperglycemia was associated with
increased venous thromboembolism in patients in the
PICU. Because 30 mg/kg of MP produced hyperglycemia
frequently but did not improve the clinical outcome, the
use of higher MP doses cannot be recommended.
Administration of corticosteroids during pediatric open
heart operations transiently decreases troponin release
compared with placebo [5–8]. The possible car-
dioprotective effect may arise from the nonnuclear effect
of corticosteroids on activation of endothelial-derived
nitric oxide synthase (eNOS) that is associated with
antiischemic properties [29]. In addition, because it is fast,
the maximal activation of eNOS is probably achieved
with a much lower steroid dose than an intravenous dose
of 30 mg/kg of MP [8, 29]. In the present study no dif-
ferences in troponin levels between the 30 and 5 mg/kg
MP groups were noted. Although our study was limited
by not measuring cardiac output with echocardiography,
no differences were noted in indirect cardiac output
measurements such as inotropic score, central venous
saturation, or lactate levels. In transgenic mouse models,
investigators observed that although normal signaling of
glucocorticoid receptor in cardiomyocytes is crucial for
the normal development and function of the heart,
overexpression of both glucocorticoid and mineralocor-
ticoid receptor activation in cardiomyocytes presents an
increased risk of arrhythmias such as atrioventricular
block, bradycardia, or increased occurrence of ventricular
arrhythmias [30]. In our study 7 patients in the MP 30 mg/
kg group received amiodarone infusion because of junc-
tional ectopic tachycardia or atrial tachycardia compared
with 2 patients in the MP 5 mg/kg group. However, this
difference was not statistically significant. The results
from our study and the finding that abnormally high
glucocorticoid activity may in theory be detrimental for
normal heart function do not support the administration
of high doses of steroids for cardioprotective reasons.
We measured plasma MP concentrations previously in
two series of children undergoing CPB [4, 8]. In the pre-
sent study, the weight of the patients with tetralogy of
Fallot was comparable to the weight of the previous pa-
tients with ventricular or atrioventricular septal defects
[8]. Consequently, administration 30 mg/kg of MP also
resulted in comparable mean total plasma MP concen-
trations [8]. On the contrary, the measured mean peakplasma concentrations of MP with similar administration
were almost twice as high as in neonates, in whom the
CPB prime volume is relatively high compared with body
surface area [4]. It is evident that the measured MP
plasma concentrations vary during CPB depending on the
patient’s size and the relative proportion of CPB prime
volume to the patient’s body surface area. Moreover, in
our previous studies the standard weight-based dosing
produced remarkable individual variability in plasma
corticosteroid concentrations [4, 8]. Therefore, more
studies and possibly the use of population pharmacoki-
netic methods are needed to optimize the dose of gluco-
corticoids during pediatric open heart operations.
Although the antiinflammatory effect of corticosteroids
was demonstrated in earlier studies, the lack of a placebo
group can be considered a limitation of the present study.
Because of the relatively small sample size, there is a
theoretical possibility for a type II error in data analyses.
The cardioplegia protocol changed during the study
period, and this change may also have influenced car-
dioprotection and troponin values. Conversely, the new
protocol was used in equal number of patients in both
study groups. The lack of echocardiographic cardiac
output data can also be regarded as a limitation of the
study. Nevertheless, we observed no differences in indi-
rect cardiac output measurements or inotropic score.
In conclusion, despite producing significantly higher
plasma MP concentrations, the administration of 30 mg/
kg of MP at anesthesia induction was not superior in
terms of antiinflammatory or cardioprotective action
compared with 5 mg/kg of MP. Conversely, the high-dose
administration exposed patients to postoperative hyper-
glycemia. The results from the present study discourage
the use of 30 mg/kg of MP during pediatric open heart
surgical procedures.
This work was financially supported by Helsinki University
Hospital. The authors wish to thank the staff of the Children’s
Hospital and the children’s parents for their contribution to this
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